8-K: Aquestive Therapeutics' Anaphylm Shows Consistent Results Regardless of Film Placement, Study Finds

Aquestive Therapeutics announced that a subsequent analysis of its Anaphylm sublingual film demonstrated comparable pharmacokinetic and pharmacodynamic data to epinephrine injection, regardless of variable placement or intraoral movement.

Summary

• Aquestive Therapeutics presented a subsequent analysis of its Anaphylm (epinephrine) Sublingual Film at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting.
• The analysis showed that Anaphylm's performance is consistent, with comparable PK and PD data to epinephrine injection, even with variable placement or movement in the mouth.
• The study found that 87.5% of subjects showed no change in film location between 1.5 to 3 minutes after administration.
• In the 12.5% of subjects where movement was noted, there were no significant differences in key metrics like Cmax (maximum concentration) or Tmax (time to maximum concentration) compared to those without movement.
• The results suggest that Anaphylm offers a reliable method of drug delivery for anaphylaxis management.

Sentiment

Score: 8

Explanation: The document presents positive results from a subsequent analysis of Anaphylm, indicating a robust and reliable product. The potential for a first-in-class no-needle, no-device oral epinephrine product is also a significant positive. However, there are risks associated with regulatory approval and commercialization, which temper the overall sentiment.

Positives

• Anaphylm's sublingual film technology demonstrates consistent drug delivery, even with minor variations in placement.
• The product has the potential to be the first FDA-approved no-needle, no-device oral epinephrine product.
• The film is small, lightweight, and dissolves on contact, requiring no water or swallowing.
• The packaging is designed to be easily carried and withstand weather conditions.
• The study showed that Anaphylm was safe and well-tolerated at the therapeutic dose.

Risks

• The company faces risks associated with the development and regulatory approval of Anaphylm, including potential delays or changes to the timing, cost, and success of clinical trials.
• There is a risk that the FDA may require additional clinical studies for approval.
• The company faces risks related to commercializing a new product, including technology, financial, market, and implementation risks.
• There are risks related to the company's ability to secure sufficient capital and cash resources.
• The company faces risks related to competition from other products, including generics.

Future Outlook

The company is focused on advancing Anaphylm through clinical development and seeking FDA approval, with the potential to be the first no-needle, no-device oral epinephrine product. They are also developing an earlier stage epinephrine prodrug topical gel for various dermatology conditions.

Management Comments

• Dan Barber, Aquestive's President and CEO, stated that the findings demonstrate the robustness and reliability of their sublingual film technology.
• He also noted that Anaphylm has the potential to offer a dependable alternative for the treatment of severe allergic reactions.

Industry Context

This announcement is significant as it addresses the need for a more convenient and reliable method of epinephrine delivery for anaphylaxis, potentially disrupting the current market dominated by auto-injectors. The sublingual film technology could offer a more user-friendly alternative for patients.

Comparison to Industry Standards

• The current standard of care for anaphylaxis treatment is epinephrine administered via auto-injectors like EpiPen and Auvi-Q, which have distinct pharmacokinetic profiles.
• Aquestive's Anaphylm aims to provide a comparable PK profile to epinephrine injection, but with the convenience of a sublingual film.
• The study results indicate that Anaphylm's performance is consistent regardless of placement or movement, which is a key advantage over traditional methods that rely on precise injection techniques.
• The company is positioning Anaphylm as a potential first-in-class no-needle, no-device oral epinephrine product, which would be a significant advancement in the field.

Stakeholder Impact

• Shareholders may view the positive study results as a positive development for the company's future prospects.
• Patients with severe allergies could benefit from a more convenient and reliable treatment option.
• Healthcare providers may have a new tool for managing anaphylaxis.
• The company's employees are working on a potentially groundbreaking product.

Next Steps

• The company will continue to advance Anaphylm through clinical development.
• They will seek FDA approval for Anaphylm.
• The company will continue to develop an earlier stage epinephrine prodrug topical gel for various dermatology conditions.

Key Dates

Keywords

Anaphylm, epinephrine, sublingual film, anaphylaxis, pharmacokinetics, pharmacodynamics, allergy, FDA, drug delivery, PharmFilm